Log In
Print
BCIQ
Print
Print this Print this
 

TV-45070 (formerly XEN402)

  Manage Alerts
Collapse Summary General Information
Company Xenon Pharmaceuticals Inc.
DescriptionTopical formulation of sodium channel sub-type Nav1.7 (SCN9A) blocker
Molecular Target Nav1.7 (SCN9A)
Mechanism of ActionNa channel blocker
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$376.0M

$41.0M

$335.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today